C12N 2760/18761
Methods of inactivation or attenuation
C12N2760/18761 (Methods of inactivation or attenuation) appears on 14 US grants and 18 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 18
- Assignees
- 17
- Inventors
- 40
- Latest grant
- 2 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 2 |
| 2005 | 2 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 0 | 2 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 2 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 2 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
Recent patents
- F-genotype mumps virus attenuated strain and construction method therefor and application thereof2 Dec 2025US 12,486,497 B2Beijing Cell-Fusion Biotechnology Co., Ltd.
- Recombinant mumps virus vaccine8 Jun 2021US 11,027,008 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Vaccine prepared utilizing human parainfluenza virus type 2 vector4 Jul 2017US 9,695,444 B2Biocomo Inc.
- Recombinant mumps virus vaccine16 May 2017US 9,649,371 B2University of Georgia Research Foundation, Inc.
- Attenuated human parainfluenza virus, methods and uses thereof19 May 2015US 9,034,343 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- F-genotype mumps virus attenuated strain and construction method therefor and application thereof8 Dec 2022US 2022/0389391 A1Beijing Cell-Fusion Biotechnology Co., Ltd.
- Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins27 Jan 2022US 2022/0023413 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Recombinant mumps virus vaccine18 Jul 2019US 2019/0216918 A1University of Georgia Research Foundation, Inc.
- Recombinant mumps virus vaccine17 Aug 2017US 2017/0232098 A1University of Georgia Research Foundation, Inc.
- Vaccine prepared utilizing human parainfluenza virus type 2 vector19 Nov 2015US 2015/0329874 A1Biocomo Inc.
Most cited
By later US patents
- Method for inactivating a virus36US 5,891,705 APentose Pharmaceuticals, Inc. · 1999
- Attenuated parainfluenza virus (PIV) vaccines11US 7,951,383 B2The United States of America as represented by the Department of Health and Human Services · 2011
- Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens4US 8,367,074 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2013
- Vaccine against mumps containing a Jeryl-Lynn virus strain2US 6,024,962 ASmithKline Beecham Biologicals s.a. · 2000
- Temperature-sensitive and cold-adapted human parainfluenza virus type 2 (HPIV-2) and vaccines based on such virus1US 6,946,136 B2St. Louis University · 2005